Compare ALH & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALH | BLTE |
|---|---|---|
| Founded | 1908 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 6.0B |
| IPO Year | 2025 | 2021 |
| Metric | ALH | BLTE |
|---|---|---|
| Price | $21.27 | $147.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 9 |
| Target Price | $31.13 | ★ $228.89 |
| AVG Volume (30 Days) | ★ 924.4K | 133.0K |
| Earning Date | 11-12-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | ★ $1,709,237,000.00 | N/A |
| Revenue This Year | $6.64 | N/A |
| Revenue Next Year | $6.19 | N/A |
| P/E Ratio | $34.61 | ★ N/A |
| Revenue Growth | ★ 13.31 | N/A |
| 52 Week Low | $18.64 | $90.84 |
| 52 Week High | $28.23 | $200.00 |
| Indicator | ALH | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 45.10 | 39.67 |
| Support Level | $20.82 | $145.21 |
| Resistance Level | $22.07 | $161.08 |
| Average True Range (ATR) | 0.55 | 5.89 |
| MACD | 0.10 | -0.37 |
| Stochastic Oscillator | 57.62 | 30.70 |
Alliance Laundry Holdings Inc is a designer and manufacturer of commercial laundry systems, serving diverse international markets. The company offers premium, durable laundry equipment under brands like Speed Queen, UniMac, Huebsch, Primus, IPSO, and others. It serves commercial laundry needs across healthcare, hotels, laundromats, and residential markets. Revenue is generated through the sale of commercial-grade laundry systems and service parts across two geographic segments, North America and International, and into the three end markets of OPL, Vended, and Commercial In-Home.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.